BUSINESS/FINANCE NEWS
Setup News Ticker
   BUSINESS/FINANCE NEWS
Searching for 'Vaccine Stock'. (Return)

MarketWatch MarketPulseAug 05, 2020
J&J to receive $1 billion in U.S. funding to make 100 million doses of its COVID-19 vaccine
Shares of Johnson & Johnson gained 0.8% in premarket trading on Wednesday after the company said it will receive more than $1 billion from the U.S. government to manufacture 100 million doses of its investigational COVID-19 vaccine. The vaccine will be provided at a "global not-for-profit basis for emergency pandemic use," J&J said. The company's vaccine candidate recently entered the Phase 1/2a clinical trial, which is taking place in Belgium and the U.S. J&J's stock is up 0.9% year-to-date, while the S&P 500 has gained 2.3%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.



RELATED ARTICLES
Moderna's stock rallies as it moves forward with enrolling its Phase 3 COVID-19 vaccine trial (MarketWatch MarketPulse)
Novavax Covid-19 Vaccine Results Send Investors on Wild Ride (Yahoo Business)

Forbes HeadlinesAug 05, 2020
Dow Jones Futures: Second Stimulus Deal Can Happen, Coronavirus Stock Market Rally Focuses On U.S.-China Tensions; Gold At A Record High
Second Stimulus hopes and US-China Tensions are the two important factors that can make or break the coronavirus stock market rally. Novavax stock went wild on vaccine data news.

Google Business NewsAug 04, 2020
Novavax Phase 1 data shows coronavirus vaccine is safe and elicits an immune response - CNN
Novavax Phase 1 data shows coronavirus vaccine is safe and elicits an immune response  CNNNovavax's coronavirus vaccine generates promising immune response in early trial, data shows  CNBCNovavax shares plunge after-hours despite positive Covid-19 vaccine data  CNBC TelevisionCoronavirus latest: Asia-Pacific stocks dip as recovery doubts boost gold  Financial TimesNovavax's Covid-19 vaccine shows promising immune response  STATView Full C
TRENDING TAGS
Coronavirusvaccine latest deal White updates
Stockearnings market beat Buy July
COVID-19vaccine results Novavax test million
Pandemicduring How Coronavirus Disney amid
DisneyBillion earnings Pandemic streaming Nearly
earningsQ2 Call Transcript Inc Stock
TikTokMicrosoft Trump China Lawsuit Ban
Goldabove record time hedge funds
ChinaTikTok US-China tensions far ahead
BillionDisney deal Teladoc Livongo Health

NEWS SOURCES
Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money
CNN/Money Real Estate News
Dismal.com: Analysis
Dismal.com: Indicators
Enterprise Application News
Entrepreneur.com
Forbes Headlines
Forbes Social Media News
FT.com - China, Economy & Trade
FT.com - Financial Markets
FT.com - Hedge Funds
FT.com - Telecoms
FT.com - US
Google Business News
Google Market News
HBS Working Knowledge
Inc.com
INSEAD Knowledge
International Tax Review
Kiplinger
Knowledge@Wharton
L.S. Starrett News
MarketWatch
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly
MSNBC.com: Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
OpinionJournal.com
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money
SEC.gov Updates: News Digest
SHRM HR News
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ US News
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC